Erik de Blois

2.7k citations

75 papers · 2.1k indexed · h-index 27

Radiology, Nuclear Medicine and Imaging top 1%
- Radiopharmaceutical Chemistry and Applications 58
- Medical Imaging Techniques and Applications 23
Oncology top 5%
- Lung Cancer Research Studies 13
- Peptidase Inhibition and Analysis 11
Epidemiology top 5%
- Neuroendocrine Tumor Research Advances 31
Pulmonary and Respiratory Medicine top 5%
- Prostate Cancer Treatment and Research 14
Neurology top 5%
- Neuroblastoma Research and Treatments 8
Cellular and Molecular Neuroscience
- Neuropeptides and Animal Physiology 5

Co-authors: Mark Konijnenberg Wouter A.P. Breeman Marion de Jong Ho Sze Chan Eric P. Krenning Simone U. Dalm Bert F. Bernard Julie Nonnekens
Cited by: Radiology, Nuclear Medicine and Imaging Oncology Epidemiology
Journals: PLoS ONE (1 paper)International Journal of Molecular Sciences (1 paper)Bone (1 paper)
Partner nations: Netherlands Germany Greece

In The Last Decade

Erik de Blois

74 papers receiving 2.1k citations

Peers

Countries citing papers authored by Erik de Blois

Since Specialization

Citations

This map shows the geographic impact of Erik de Blois's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik de Blois with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik de Blois more than expected).

Fields of papers citing papers by Erik de Blois

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik de Blois. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik de Blois. The network helps show where Erik de Blois may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Erik de Blois, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Erik de Blois Line = papers co-authored together Erik de Blois links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	IAEA activities to support the member states in the production of targeted alpha therapy radiopharmaceuticals Nuclear Medicine and Biology ·Amir Reza Jalilian,Janke Kleynhans,Penelope Bouziotis,Frank Bruchertseifer,Sudipta Chakraborty,Erik de Blois,Melissa A. Denecke,Umut Elboğa,Mohamed A. Gizawy,Celina Horak,Jinsun Jang,Aruna Korde,Agnieszka Majkowska‐Pilip,Amanda Mdlophane,Blanca Ocampo‐García,Svetlana V. Selivanova,Valeriia N. Starovoitova,W. Wojdowska,Jan Rijn Zeevaart,Valery Radchenko	2025	2
2	Ac-225 radiochemistry through the lens of [225Ac]Ac-DOTA-TATE EJNMMI Radiopharmacy and Chemistry ·Eline Hooijman,J. R. de Jong,Carolline Ntihabose,Frank Bruchertseifer,Aliyah Morgenstern,Yann Seimbille,Tessa Brabander,Stijn L.W. Koolen,Erik de Blois	2025	4
3	First real-world clinical experience with [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria European Journal of Nuclear Medicine and Molecular Imaging ·Sui Wai Ling,Quido G. de Lussanet,M. Ananta,Erik de Blois,Stijn L.W. Koolen,Roosmarijn C. Drexhage,Johannes Hofland,Debbie Robbrecht,Astrid A M van der Veldt,Frederik A. Verburg,Tessa Brabander	2025	2
4	[212Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors Pharmaceuticals ·Dylan Chapeau,Sofia Koustoulidou,Maryana Handula,Savanne Beekman,Corrina de Ridder,Debra Stuurman,Erik de Blois,Yulia Buchatskaya,Karlijn van der Schilden,Marion de Jong,Mark Konijnenberg,Yann Seimbille	2023	11
5	The Balance Between the Therapeutic Efficacy and Safety of [177Lu]Lu-NeoB in a Preclinical Prostate Cancer Model Molecular Imaging and Biology ·Marjolein Verhoeven,Joost Haeck,Erik de Blois,Francesca Orlandi,Donato Barbato,Mattia Tedesco,Mark Konijnenberg,Simone U. Dalm	2023	7
6	Improved postprocessing of dynamic glucose-enhanced CEST MRI for imaging brain metastases at 3 T European Radiology Experimental ·Yulun Wu,Sophie H. A. E. Derks,Tobias Wood,Erik de Blois,Astrid A.M. van der Veldt,Marion Smits,Esther A. H. Warnert	2023	2
7	DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo Theranostics ·Thom G. A. Reuvers,Nicole S. Verkaik,Debra Stuurman,Corrina de Ridder,Marian C. Clahsen‐van Groningen,Erik de Blois,Julie Nonnekens	2023	8
8	Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer Pharmaceutics ·Sui Wai Ling,Erik de Blois,Eline Hooijman,Astrid van der Veldt,Tessa Brabander	2022	44
9	Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity European Journal of Nuclear Medicine and Molecular Imaging ·Eline A. M. Ruigrok,Marjolein Verhoeven,Mark Konijnenberg,Erik de Blois,Corrina M.A. de Ridder,Debra Stuurman,Luisa Bertarione,Katia Rolfo,Marion de Jong,Simone U. Dalm	2022	23
10	Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [177Lu]Lu-PSMA EJNMMI Radiopharmacy and Chemistry ·Eline Hooijman,Carolline Ntihabose,Thom G. A. Reuvers,Julie Nonnekens,Else A. Aalbersberg,Jordy R. J. P. van de Merbel,Judith E. Huijmans,Stijn L.W. Koolen,Jeroen J. M. A. Hendrikx,Erik de Blois	2022	16
11	In Vivo Evaluation of Gallium-68-Labeled IRDye800CW as a Necrosis Avid Contrast Agent in Solid Tumors Contrast Media & Molecular Imaging ·Marcus C. M. Stroet,Erik de Blois,Joost Haeck,Yann Seimbille,Laura Mezzanotte,Marion de Jong,Clemens W.G.M. Löwik,Kranthi M. Panth	2021	5
12	Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC Pharmaceutics ·Eline Hooijman,Yozlem Chalashkan,Sui Wai Ling,Figen F. Kahyargil,Marcel Segbers,Frank Bruchertseifer,Aliyah Morgenstern,Yann Seimbille,Stijn L.W. Koolen,Tessa Brabander,Erik de Blois	2021	36
13	GRPr Antagonist ⁶⁸Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naïve Patients Journal of Nuclear Medicine ·Ingrid L. Bakker,Alida Fröberg,Martijn B. Busstra,J. Fred Verzijlbergen,Mark Konijnenberg,Geert J.L.H. van Leenders,Ivo G. Schoots,Erik de Blois,Wytske M. van Weerden,Simone U. Dalm,Θεοδοσία Μάινα,Berthold A. Nock,Marion de Jong	2021	31
14	In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer Molecular Imaging and Biology ·Ingrid L. Bakker,Sandra T. van Tiel,Joost Haeck,Gabriela N. Doeswijk,Erik de Blois,Marcel Segbers,Θεοδοσία Μάινα,Berthold A. Nock,Marion de Jong,Simone U. Dalm	2018	14
15	Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine EJNMMI Research ·Ho Sze Chan,Mark Konijnenberg,Tamara Daniels,Monique Nysus,Mehran Makvandi,Erik de Blois,Wouter A.P. Breeman,Robert W. Atcher,Marion de Jong,Jeffrey P. Norenberg	2016	54
16	In Vitro and In Vivo Application of Radiolabeled Gastrin-Releasing Peptide Receptor Ligands in Breast Cancer Journal of Nuclear Medicine ·Simone U. Dalm,John W.M. Martens,Anieta M. Sieuwerts,Carolien H. M. van Deurzen,Stuart Koelewijn,Erik de Blois,Θεοδοσία Μάινα,Berthold A. Nock,Luc Brunel,Jean‐Alain Fehrentz,Jean Martínez,Marion de Jong,Marleen Melis	2015	56
17	In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies Theranostics ·Kristell L.S. Chatalic,Mark Konijnenberg,Julie Nonnekens,Erik de Blois,Sander Hoeben,Corrina de Ridder,Luc Brunel,Jean‐Alain Fehrentz,Jean Martínez,Dik C. van Gent,Berthold A. Nock,Θεοδοσία Μάινα,Wytske M. van Weerden,Marion de Jong	2015	53
18	Investigation of Factors Determining the Enhanced Permeability and Retention Effect in Subcutaneous Xenografts Journal of Nuclear Medicine ·Michiel Bolkestein,Erik de Blois,Stuart Koelewijn,Alexander Eggermont,Frank Grosveld,Marion de Jong,Gerben A. Koning	2015	39
19	In Vivo Enzyme Inhibition Improves the Targeting of [ ¹⁷⁷ Lu]DOTA-GRP(13–27) in GRPR-Positive Tumors in Mice Cancer Biotherapy and Radiopharmaceuticals ·Panteleimon J. Marsouvanidis,Marleen Melis,Erik de Blois,Wout A. P. Breeman,Eric P. Krenning,Θεοδοσία Μάινα,Berthold A. Nock,Marion de Jong	2014	10
20	Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression Bone ·M. Siebelt,J.H. Waarsing,Harald C. Groen,Cristina Müller,Stuart Koelewijn,Erik de Blois,Jan A.N. Verhaar,Marion de Jong,Harrie Weinans	2014	63

About Erik de Blois

Erik de Blois is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Epidemiology, having authored 75 papers that have together received 2.1k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (58 papers), Neuroendocrine Tumor Research Advances (31 papers), Medical Imaging Techniques and Applications (23 papers), Prostate Cancer Treatment and Research (14 papers), Lung Cancer Research Studies (13 papers), Peptidase Inhibition and Analysis (11 papers), Neuroblastoma Research and Treatments (8 papers) and Neuropeptides and Animal Physiology (5 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (1.4k citations), Oncology (888 citations) and Epidemiology (724 citations). Erik de Blois has collaborated with scholars based in Netherlands, Germany and Greece. Frequent co-authors include Mark Konijnenberg, Wouter A.P. Breeman, Marion de Jong, Ho Sze Chan, Eric P. Krenning, Marion de Jong, Simone U. Dalm, Bert F. Bernard, Julie Nonnekens and Θεοδοσία Μάινα. Their work appears in journals such as PLoS ONE, International Journal of Molecular Sciences and Bone.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact